Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The event is scheduled for February 11-12, 2025 in Snowbird, Utah.
CEO Dan Goldberger will be available for one-on-one meetings throughout the conference. Interested investors can arrange meetings through their BTIG representative or by contacting electroCore's investor relations team directly at investors@electrocore.com.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced the issuance of five new U.S. patents by the USPTO between December 17, 2024, and December 31, 2024.
These patents include:
- US Patent No. 12,168,128 - Issued on December 17, 2024, it covers systems and methods for treating medical conditions by transmitting electrical impulses to the trigeminal nerve, controlled via a mobile device.
- US Patent No. 12,168,121 - Also issued on December 17, 2024, it relates to treating developmental disorders in fetuses by delivering electrical impulses to a nerve in pregnant women.
- US Patent No. 12,172,015 - Issued on December 24, 2024, it involves a medical device generating electrical impulses and using a smart card for refilling the device after specific usage.
- US Patent No. 12,172,016 - Issued on December 24, 2024, it pertains to non-invasive vagal nerve stimulation for treating Parkinson's disease.
- US Patent No. 12,179,012 - Issued on December 31, 2024, it describes a device for non-invasive nerve stimulation, transmitting electrical impulses through the skin to a target nerve.
These patents enhance electroCore's intellectual property portfolio, potentially strengthening its market position in bioelectronic medicine.
electroCore (ECOR) has announced a definitive agreement to acquire NeuroMetrix (NURO), focusing on its Quell platform while excluding the DPNCheck business. The acquisition aims to strengthen electroCore's position in the bioelectronic health and wellness sector. Quell is a wearable neuromodulation platform FDA-authorized for fibromyalgia symptoms and lower-extremity chronic pain treatment.
The transaction value will equal NURO's net cash balance at closing, with NURO shareholders receiving non-tradeable contingent value rights (CVRs). Each CVR includes rights to DPNCheck divestiture proceeds and up to $500,000 in Quell product royalties over two years post-closing. The deal is expected to close by Q1 2025, subject to NURO shareholder approval.
NeuroMetrix reported Q3 2024 results with total revenue of $600,000, including Quell revenue of $184,000 (50% YoY increase), and a net loss of $1.5 million.
electroCore (Nasdaq: ECOR) announces that its wellness product Truvaga Plus has received recognition in the first-ever Woman's World Magazine 50 over 50 Award. The award evaluation criteria included quality, effectiveness, and value, specifically targeting products beneficial for women over 50. The product is designed to help reduce stress, enhance sleep quality, and improve mental focus. CEO Dan Goldberger expressed pride in this recognition, emphasizing the company's commitment to developing solutions that enhance quality of life.
electroCore (Nasdaq: ECOR) has donated 20 gammaCore Sapphire D devices for a real-world evaluation of non-invasive vagus nerve stimulation (nVNS) among Israelis dealing with trauma. The study will be conducted by Dr. Yori Gidron from the University of Haifa and Dr. Robin Ely, Director of Integrative and Regenerative Medicine. Dr. Gidron, co-author of the PTSD Clinical Practice Guideline published by the Vagus Nerve Society, notes that PTSD is a debilitating psychiatric condition stemming from traumatic events, and nVNS presents a novel therapeutic solution.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 in New York City. Joshua Lev, Chief Financial Officer, will be available for one-on-one meetings throughout the event. Interested investors can arrange meetings through their Canaccord Genuity representatives.
electroCore reported record Q3 2024 financial results with revenue of $6.6 million, up 45% year-over-year. The growth was primarily driven by a 75% increase in Rx gammaCore™ sales in VA/DoD and a 147% rise in Truvaga™ sales. The company's net loss decreased 38% to $2.5 million compared to Q3 2023. Gross profit reached $5.5 million with an 84% margin. Cash position strengthened to $13.2 million as of September 30, 2024. Operating expenses remained stable at $8.1 million, while net cash used in operations decreased 51% to $5.7 million for the first nine months of 2024.
ElectroCore (Nasdaq: ECOR) has announced that its wellness product, Truvaga Plus, has received the Men's Health Magazine Tech Award. The award recognizes innovative wellness devices that make significant contributions to men's health and wellness. The product is designed to manage stress, enhance sleep, and improve mental focus. CEO Dan Goldberger expressed pride in receiving this prestigious recognition, emphasizing the company's dedication to developing life-improving solutions.
electroCore (NASDAQ: ECOR) announced the appointment of Thomas Freeburg as VP, Corporate Controller, effective November 11, 2024. The company's Compensation Committee granted him 5,000 restricted stock units (RSUs) as an inducement for employment under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest equally over three years, with 33% vesting on each anniversary of the grant date, contingent on continued employment. Upon vesting, the RSUs will convert to common stock shares.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has scheduled its third quarter 2024 financial results announcement for Wednesday, November 13, 2024, after market close. The company will host a conference call and webcast at 4:30 PM EST for management to discuss results and take questions. Participants can join via phone using dial-in numbers 877-407-8835 (domestic) or +1 201-689-8779 (international) with Conference ID 13744121.